Modality
Nanobody
MOA
FXIai
Target
SHP2
Pathway
Complement
NarcolepsyFSGSMDS
Development Pipeline
Preclinical
Mar 2019
→ Dec 2030
PreclinicalCurrent
NCT05871806
1,753 pts·FSGS
2019-03→2030-12·Terminated
1,753 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-074.7y awayInterim· FSGS
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2030-12-07 · 4.7y away
FSGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05871806 | Preclinical | FSGS | Terminated | 1753 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D |